AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT02319668
Drug: Sodium fluoride toothpaste (Aquafresh Mild & Minty)
RxNorm normalized name: sodium fluoride Toothpaste
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will apply a strip of toothpaste to cover the head of the toothbrush and will brush in their usual manner for two timed minutes twice daily. They will then rinse their mouth thoroughly with water after brushing
Trial: NCT00117546
Drug: alpha methyldopa
RxNorm normalized name: Methyldopa
DrugBank: Methyldopa (DB00968)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 500 mg twice a day
Trial: NCT02475070
Drug: Vildagliptin
RxNorm normalized name: Vildagliptin
DrugBank: Vildagliptin (DB04876)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Vildagliptin added at 50 mg twice daily for two weeks followed by four weeks washout and then dapagliflozin 10mg once daily for two weeks
Trial: NCT02475070
Drug: Dapagliflozin
RxNorm normalized name: Dapagliflozin
DrugBank: Dapagliflozin (DB06292)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Dapagliflozin added at 10 mg once daily for two weeks followed by four weeks washout and then vildagliptin 50 mg twice daily for two weeks
Trial: NCT00865696
Drug: Mirtazapine 15 mg tablets, single dose
DrugBank: Mirtazapine (DB00370)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A: Experimental Subjects received Purepac formulated products under fasting conditions
Trial: NCT00004047
Drug: exatecan mesylate
RxNorm normalized name: mesylate
DrugBank: Exatecan (DB12185)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02621060
Drug: Chlorogenic acid
RxNorm normalized name: chlorogenic acid
DrugBank: Chlorogenic Acid (DB12029)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chologenic acid: 1200 mg per day for three months
Trial: NCT01471470
Drug: Docetaxel, Capecitabine, Cisplatin, Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab 7.5mg/kg IV (D1) Docetaxel 60 mg/m2 IV (D1) Cisplatin 60 mg/m2 IV (D1) Xeloda 1,875 mg/m2/day/bid PO (D1-D14)
Trial: NCT03991000
Drug: Ferric carboxymaltose
RxNorm normalized name: Ferric Carboxymaltose
DrugBank: Ferric carboxymaltose (DB08917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous iron
Trial: NCT03991000
Drug: Saline
RxNorm normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Saline application according to dosing rules of iron.
Trial: NCT03092206
Drug: F/TAF
RxNorm normalized name: Emtricitabine/Tenofovir Alafenamide
DrugBank: Emtricitabine (DB00879)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: antiretroviral therapy
Trial: NCT01101880
Drug: clofarabine
RxNorm normalized name: Clofarabine
DrugBank: Clofarabine (DB00631)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Given IV
Trial: NCT01101880
Drug: cytarabine
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT04329403
Drug: Adapalene 0.1% Gel
RxNorm normalized name: ADAPALENE 0.1% GEL,TOP
DrugBank: Adapalene (DB00210)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A thin film of the assigned medication to be applied once daily in the evening for 12 weeks
Trial: NCT01750931
Drug: Mobic 15mg
RxNorm normalized name: Mobic 15mg Tablet
DrugBank: Meloxicam (DB00814)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: To demonstrate the bioequivalence of Meloxicam 15 mg tablets manufactured by Savipharm J.S.C, Vietnam and Mobic® 15 mg tablets of Boehringer Ingelheim Pharma GmbH \& Co.KG Binger Str.173, 5521 Ingelheim am Rhein, Germany, in healthy adult human male subjects under fed condition
Trial: NCT02512809
Drug: Isoflurane
RxNorm normalized name: Isoflurane
DrugBank: Isoflurane (DB00753)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02512809
Drug: Dexmedetomidine
RxNorm normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03241199
Drug: Imatinib Mesylate
RxNorm normalized name: Imatinib Mesylate
DrugBank: Imatinib (DB00619)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: a first-generation tyrosine kinase inhibitors
Trial: NCT02207998
Drug: Homeopathic complex and physiotherapy
RxNorm normalized name: hesperidin complex
DrugBank: Citrus bioflavonoids (DB14586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Homoeopathic complex (Arnica montana 6CH, Bryonia alba 6CH, Causticum 6CH, Kalmia latifolia 6CH, Rhus toxicodendron 6CH and Calcarea fluoride 6CH) will comprise of medicated lactose tablets.
Trial: NCT04001075
Drug: TJ107
RxNorm normalized name: Tofacitinib
DrugBank: Tofacitinib (DB08895)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients enrolled in dose escalation part will be given 2 doses (28 days/dose) during the main-treatment period
Trial: NCT01921920
Drug: Omeprazole
RxNorm normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Omeprazole 20 mg (AstraZeneca - test) Omeprazole 40 mg (AstraZeneca - test) Omeprazole 20 (Merck - reference) Omeprazole 40mg (Merck - reference)
Trial: NCT00724256
Drug: ceftibuten
RxNorm normalized name: Ceftibuten
DrugBank: Ceftibuten (DB01415)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ceftibuten 9mg/kg once a day for 7 days.
Trial: NCT00724256
Drug: ceftibuten
RxNorm normalized name: Ceftibuten
DrugBank: Ceftibuten (DB01415)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ceftibuten 9mg/kg once a day for 10 days.
Trial: NCT02086188
Drug: Mirabegron
RxNorm normalized name: Mirabegron
DrugBank: Mirabegron (DB08893)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: see detailed information in associated Arm Description
Trial: NCT01970046
Drug: Placebo/Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: * Run in period ：placebo and metformin 500 mg t.i.d for 6 weeks~* Phase A : Placebo and metformin 500 mg t.i.d for 24 weeks~* Phase B : SP2086 50 mg b.i.d and metformin 500 mg t.i.d for 28 weeks
Trial: NCT01149629
Drug: Droxidopa
RxNorm normalized name: Droxidopa
DrugBank: Droxidopa (DB06262)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: One capsule containing 300 mg droxidopa, given once
Trial: NCT01149629
Drug: Droxidopa
RxNorm normalized name: Droxidopa
DrugBank: Droxidopa (DB06262)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 3 capsules each containing 100 mg droxidopa, give 3 times at 4 hour intervals
Trial: NCT01149629
Drug: Droxidopa
RxNorm normalized name: Droxidopa
DrugBank: Droxidopa (DB06262)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 3 capsules each containing 100 mg droxidopa, given once
Trial: NCT01638988
Drug: Metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 1. cycle 2000 mg of Metformin : Day 1 to day 30; beginning with 1/2 tablet by day with an increasing until 4 pills by day~2. to 6 cycle 2000 mg of Metformin : Day 1 ot day 30; 4 pills of Metformin by day Positive pregnancy test : 4 pills of Metformin by day until 12 weeks of pregnancy
Trial: NCT01638988
Drug: Clomiphene citrate
RxNorm normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cycle 1: Day 3 to day 7; 50 mg; 1 tablet of Clomiphene Citrate by day Cycle 2: Day 3 to day 7; 100 mg; 1 tablet of Clomiphene Citrate two times a day Cycle 3 to 6 : Day 3 to day 7; 150 mg; 1 tablet of Clomiphene Citrate 3 times a day
Trial: NCT00150293
Drug: Pregabalin
RxNorm normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT01378104
Drug: peginterferon alfa 2a (pegasys)
RxNorm normalized name: Peginterferon Alfa-2A
DrugBank: Interferon alfa (DB05258)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: dosage form; 180ug/week during first 12 weeks and then 135 ug/week during 36 weeks otherwise unremarkable
Trial: NCT01378104
Drug: peginterferon alfa-2a (pegasys)
RxNorm normalized name: Peginterferon Alfa-2A
DrugBank: Peginterferon alfa-2a (DB00008)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: These patients would be treated with standard dose 180ug /week for 48 weeks. In general, the patient with CHC genotype 1is guided with treatment with pegasys 180ug /week and ribavirin 1000-1200 mg/day for 48 weeks. We do not make intervention of ribavirin dose.
Trial: NCT02290626
Drug: Elmental diet
RxNorm normalized name: casein, emmental cultured
DrugBank: Casein (DB10516)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: elemental diet is administered using PEG.
Trial: NCT01536951
Drug: moxifloxacin
RxNorm normalized name: Moxifloxacin
DrugBank: Moxifloxacin (DB00218)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT03471078
Drug: Avatrombopag
RxNorm normalized name: AVATROMBOPAG
DrugBank: Avatrombopag (DB11995)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral avatrombopag tablet
Trial: NCT01727271
Drug: Tenofovir
RxNorm normalized name: Tenofovir
DrugBank: Tenofovir (DB14126)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01938547
Drug: clevidipine
RxNorm normalized name: Clevidipine
DrugBank: Clevidipine (DB04920)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02248597
Drug: fludarabine phosphate
RxNorm normalized name: Fludarabine Phosphate
DrugBank: Fludarabine (DB01073)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT00514163
Drug: gemcitabine + S-1
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: gemcitabine on day one and 8th S-1 po days 1 to14 every 3 weeks
Trial: NCT00514163
Drug: gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: gemcitabine DIV on day one , 8th and 15th
Trial: NCT00397033
Drug: Paliperidone ER
RxNorm normalized name: Paliperidone ER
DrugBank: Paliperidone (DB01267)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 6mg/day paliperidone er for 6 weeks
Trial: NCT00397033
Drug: Paliperidone ER
RxNorm normalized name: Paliperidone ER
DrugBank: Paliperidone (DB01267)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 12mg/day paliperidone er for 6 weeks
Trial: NCT01564407
Drug: ICX-RHY-013
RxNorm normalized name: ICX-RHY
DrugBank: ICX-RHY (DB05716)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug Dosing for Cohorts as follows:~Cohorts (N=4)~Safety Cohort 1:~1. Empty control no injection~2. Vehicle only (0.5 ml of HypoThermosol solution)~3. 5 million cells / cm² , single administration at Day 0~4. 5 million cells/ cm² , single administration at week 4~5. 5 million cells/cm² , single administration at Day 0 , repeat administration of this dose @ week 4~At day 0, the subject will receive a total of 3 different injections and at week 4 the subject will receive a total of 2 different injections.~Cohort 2: 2.5 million cells/ cm2, single administration Cohort 3: 5 million cells /cm2, single administration Cohort 4: 2.5 million cells/ cm2, repeat dose administration @ 4 weeks Cohort 5: 5million cells / cm2 repeat dose administration @ 4 weeks
Trial: NCT02248597
Drug: busulfan
RxNorm normalized name: Busulfan
DrugBank: Busulfan (DB01008)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT02248597
Drug: tacrolimus
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02248597
Drug: mycophenolate mofetil
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02836847
Drug: GEMOX
RxNorm normalized name: Hemox A
DrugBank: Aluminum chloride (DB11081)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional chemotherapy:gemcitabine and oxaliplatin
Trial: NCT02836847
Drug: Cetuximab
RxNorm normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT02836847
Drug: Trastuzumab
RxNorm normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT02836847
Drug: Gefitinib
RxNorm normalized name: Gefitinib
DrugBank: Gefitinib (DB00317)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00078325
Drug: Armodafinil 250 mg/day
DrugBank: Modafinil (DB00745)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Armodafinil 250 mg once daily in the morning
Trial: NCT00078325
Drug: Armodafinil 150 mg/day
DrugBank: Modafinil (DB00745)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Armodafinil 150 mg once daily in the morning
Trial: NCT01473563
Drug: Pemetrexed
RxNorm normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Administered intravenously
Trial: NCT00502346
Drug: PM10
RxNorm normalized name: VPM1002
DrugBank: VPM1002 (DB15801)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01001468
Drug: VB-201
RxNorm normalized name: VB-201
DrugBank: VB-201 (DB15259)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single daily dose of oral VB-201 20 mg
Trial: NCT02836847
Drug: Lapatinib
RxNorm normalized name: Lapatinib
DrugBank: Lapatinib (DB01259)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT02836847
Drug: Everolimus
RxNorm normalized name: Everolimus
DrugBank: Everolimus (DB01590)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT02836847
Drug: Sorafenib
RxNorm normalized name: Sorafenib
DrugBank: Sorafenib (DB00398)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02836847
Drug: Crizotinib
RxNorm normalized name: Crizotinib
DrugBank: Crizotinib (DB08865)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT04587778
Drug: Ketamine Hydrochloride
RxNorm normalized name: Ketamine Hydrochloride
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: intravenous infusion
Trial: NCT04587778
Drug: Esketamine
RxNorm normalized name: ESKETAMINE
DrugBank: Esketamine (DB11823)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: intravenous infusion
Trial: NCT01001468
Drug: VB-201
RxNorm normalized name: VB-201
DrugBank: VB-201 (DB15259)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single daily dose or oral VB-201 80 mg
Trial: NCT03054922
Drug: Lactated Ringer
RxNorm normalized name: lactated ringers
DrugBank: COVID-19 Nucleocapsid-GM-CSF Protein Lactated Ringer's Injection (DB15845)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV infusion of lactated ringer throughout surgery.
Trial: NCT04587778
Drug: Pilot study II: Esketamine
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: intravenous infusion
Trial: NCT01269801
Drug: onabotulinumtoxinA
RxNorm normalized name: Onabotulinumtoxina
DrugBank: Botulinum toxin type A (DB00083)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: * Group 1 will initially receive BOTOX® Cosmetic or VISTABEL® injections to the affected facial regions;~* Group 2 will initially receive JUVÉDERM® Ultra XC or JUVÉDERM® Ultra 2 (for moderate facial lines or folds) or JUVÉDERM® Ultra Plus XC or JUVÉDERM® Ultra 3 (for severe facial lines or folds) injections to the affected facial regions.~At 4 weeks,Group 1 patients who initially received BOTOX® Cosmetic or VISTABEL® treatment will be crossed over and receive JUVÉDERM® treatment, and Group 2 patients who initially received JUVÉDERM® treatment will be crossed over to receive BOTOX® Cosmetic or VISTABEL® treatment.
Trial: NCT05513625
Drug: Pritelivir
RxNorm normalized name: Pritelivir
DrugBank: Pritelivir (DB11844)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral administration
Trial: NCT05513625
Drug: ESO and pritelivir
RxNorm normalized name: cytarabine and daunorubicin
DrugBank: Pritelivir (DB11844)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral administration
Trial: NCT02693522
Drug: somatropin
RxNorm normalized name: Somatropin
DrugBank: Somatotropin (DB00052)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subcutaneous injection
Trial: NCT02693522
Drug: Eutropin
RxNorm normalized name: lutropin alfa
DrugBank: Lutropin alfa (DB00044)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subcutaneous injection
Trial: NCT03574753
Drug: ABBV-399
RxNorm normalized name: ABBV-514
DrugBank: ABBV-514 (DB17586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABBV-399 (Process II), 2.7 mg/kg IV over 30 ± 10 minutes, Day 1, Every 21 days
Trial: NCT00020618
Drug: morphine sulfate
RxNorm normalized name: Morphine Sulfate
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01037660
Drug: Metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Metformin 1 gram per day
Trial: NCT01970046
Drug: SP2086 50 mg b.i.d/Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: * Run-in period: placebo and Metformin 500 mg t.i.d for 6weeks~* Phase A:SP2086 50 mg b.i.d and Metformin 500 mg t.i.d for 24 weeks~* Phase B:SP2086 50 mg b.i.d and Metformin 500 mg t.i.d for 28 weeks
Trial: NCT00121433
Drug: leptin
RxNorm normalized name: Leptin
DrugBank: Leptin (DB05098)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01274663
Drug: PF-05175157 or Placebo
RxNorm normalized name: PF-05175157
DrugBank: PF-05175157 (DB12096)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One dose of PF-05175157 will be administered as a powder-in-capsule in the fasting state in the AM; correspondingly, one dose of a matched powder-in-capsule placebo will be administered in the fasting state in the AM.
Trial: NCT01274663
Drug: PF-05175157 or Placebo
RxNorm normalized name: PF-05175157
DrugBank: PF-05175157 (DB12096)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One dose of PF-05175157 will be administered as a powder-in-capsule immediately after breakfast; correspondingly, one dose of a matched powder-in-capsule placebo will be administered immediately after breakfast.
Trial: NCT01304095
Drug: Ranolazine
RxNorm normalized name: Ranolazine
DrugBank: Ranolazine (DB00243)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients in the ranolazine arm would start with 500 mg po BID of ranolazine and be force titrated to 1gm po BID after 2 weeks. Down-titration would only be allowed for side effects. This would be on top of all standard medical therapy.
Trial: NCT03057613
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 200mg every 3 weeks for 16 weeks given by IV infusion
Trial: NCT01710995
Drug: Zegerid
RxNorm normalized name: Zegerid
DrugBank: Omeprazole (DB00338)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01710995
Drug: Losec
RxNorm normalized name: Losec
DrugBank: Omeprazole (DB00338)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02341638
Drug: BMS-986141
RxNorm normalized name: BMS-986141
DrugBank: BMS-986141 (DB14942)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02341638
Drug: Aspirin
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02341638
Drug: Itraconazole
RxNorm normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01829971
Drug: MRX34
RxNorm normalized name: Miravirsen
DrugBank: Miravirsen (DB12851)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: micro RNA therapy
Trial: NCT04087590
Drug: Formoterol-glycopyrronium co suspension (PT003)
RxNorm normalized name: formoterol / glycopyrronium
DrugBank: Formoterol (DB00983)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Formoterol-glycopyrronium co suspension (PT003) in a Metered Dose Inhaler, 2 puffs twice daily
Trial: NCT02453373
Drug: Magnesium Sulfate
RxNorm normalized name: Magnesium Sulfate
DrugBank: Magnesium sulfate (DB00653)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Magnesium sulfate will be administered intravenously as needed to control shivering
Trial: NCT02453373
Drug: tPA
RxNorm normalized name: tPA
DrugBank: Alteplase (DB00009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: tPA will be administered intravenously if indicated
Trial: NCT02453373
Drug: Propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Induction doses of propofol or etomidate will be used to aid in the suppression of patient discomfort
Trial: NCT02453373
Drug: Etomidate
RxNorm normalized name: Etomidate
DrugBank: Etomidate (DB00292)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Induction doses of propofol or etomidate will be used to aid in the suppression of patient discomfort
Trial: NCT02473640
Drug: SYN-004
RxNorm normalized name: .beta.-lactamase (synthetic bacillus licheniformis isoenzyme syn-004)
DrugBank: Ribaxamase (DB16311)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02473640
Drug: Esomeprazole
RxNorm normalized name: Esomeprazole
DrugBank: Esomeprazole (DB00736)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02473640
Drug: Ceftriaxone
RxNorm normalized name: Ceftriaxone
DrugBank: Ceftriaxone (DB01212)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02472522
Drug: Ropivacaine + Dexmedetomidine
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients satisfying inclusion criteria will receive Subarachnoid Block with Bupivacaine Heavy 0.5% (11 mg/2.2 ml) with 25 micrograms of fentanyl. At the end of the procedure, bilateral TAP block will be performed using Landmark Technique with 2.5 mg/kg of ropivacaine and 1 micrograms/kg dexmedetomidine (combination drug) diluted with 0.9% saline to a total volume of 40 ml (20 ml each side) for the TAP block
Trial: NCT02447055
Drug: Melphalan
RxNorm normalized name: Melphalan
DrugBank: Melphalan (DB01042)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02447055
Drug: Fludarabine
RxNorm normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02447055
Drug: Tacrolimus
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02447055
Drug: Mycophenolate mofetil
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02447055
Drug: Filgrastim
RxNorm normalized name: Filgrastim
DrugBank: Filgrastim (DB00099)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT02254577
Drug: Endometrin® plus Progesterone in Oil (PIO)
DrugBank: Progesterone (DB00396)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02254577
Drug: Progesterone in Oil (PIO) Only
RxNorm normalized name: Progesterone
DrugBank: Progesterone (DB00396)
FDA approved: yes
EMA approved: no
PMDA approved: yes